Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inari Medical Inc (NARI)

Inari Medical Inc (NARI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Inari Medical Inc 6001 Oak Canyon Suite 100 Irvine CA 92618 USA

www.inarimedical.com Employees: 1,300 P: 877-923-4747

Description:

Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.

Key Statistics

Overview:

Market Capitalization, $K 2,912,564
Enterprise Value, $K 2,873,354
Shares Outstanding, K 58,544
Annual Sales, $ 493,630 K
Annual Net Income, $ -1,640 K
Last Quarter Sales, $ 153,390 K
Last Quarter Net Income, $ -18,370 K
EBIT, $ -55,070 K
EBITDA, $ -57,570 K
60-Month Beta 0.96
% of Insider Shareholders 10.60%
% of Institutional Shareholders 90.98%
Float, K 52,338
% Float 89.40%
Short Volume Ratio 0.47

Growth:

1-Year Return -15.93%
3-Year Return -39.06%
5-Year Return 0.00%
5-Year Revenue Growth 7,127.38%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.13 on 10/28/24
Next Earnings Date N/A
Earnings Per Share ttm -0.75
EPS Growth vs. Prev Qtr 68.29%
EPS Growth vs. Prev Year -360.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NARI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -10.09%
Return-on-Assets % -6.60%
Profit Margin % -0.33%
Debt/Equity 0.00
Price/Sales 5.81
Price/Cash Flow 555.72
Price/Book 6.60
Book Value/Share 7.43
Interest Coverage 22.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar